# US 2024/0200137 A1 · Method for the prognosis and/or diagnosis of a disease based on a sample of adipose tissue, and a kit for said method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200137 A1
- Document ID: US20240200137A1
- Status: Published application
- Kind: A1
- Application number: 18/067,995
- Filed: 2022-12-19
- Published: 2024-06-20
- Earliest claimed: 2015-04-30
- Assignees: Lipozyt Marker Ug
- Applicants: Lipozyt Marker Ug
- Inventors: Helge Wilhelm THIES; Markus KLEMKE
- Web page: https://patentgrep.com/patent/US20240200137A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention relates to a method for the prognosis of adiposity and the prognosis and/or diagnosis of a disease selected from the group consisting of diabetes, cardiovascular diseases and metabolic syndrome

## Claims

### Claim 1

A method of determining adipose tissue composition with respect to a proportion of pre-adipocytes and a proportion of mature insulin-sensitive adipocytes in adipose tissue of an individual and assessing risk of developing type II diabetes mellitus comprising the steps of:
determining a mean of expression of high mobility group AT-hook 2 (HMGA2) and peroxisome proliferator-activated receptor gamma (PPAR-gamma) in adipose tissue of a group of test subjects having type II diabetes mellitus comprising the steps of
a) puncturing the subcutaneous abdominal adipose tissue of each test subject of the group of test subjects having type II diabetes mellitus to obtain a sample of adipose tissue from the test subject,
b) extracting nucleic acid from the adipose tissue sample, wherein the sample mass is ≤50 mg and wherein the nucleic acid is RNA;
c) denaturing the RNA,
d) reverse transcribing the denatured RNA into cDNA,
e) pre-amplifying the cDNA, and
f) measuring gene expression level of HMGA2 via polymerase chain reaction (PCR);
g) measuring gene expression level of PPAR-gamma via PCR;
h) calculating the mean of expression of HMGA2 and PPAR-gamma in adipose tissue of the group of test subjects having type II diabetes mellitus;
obtaining a gene expression profile of HMGA2 and PPAR-gamma in adipose tissue of the individual comprising the steps of:
a) puncturing the subcutaneous abdominal adipose tissue of the individual having type II diabetes mellitus to obtain a sample of adipose tissue from the individual,
b) extracting nucleic acid from the adipose tissue sample, wherein the sample mass is <50 mg and wherein the nucleic acid is RNA;
c) denaturing the RNA,
d) reverse transcribing the denatured RNA into cDNA,
e) pre-amplifying the cDNA, and
f) measuring gene expression level of HMGA2 via polymerase chain reaction (PCR);
g) measuring gene expression level of PPAR-gamma via PCR;
h) constructing the gene expression profile of HMGA2 and PPAR-gamma in adipose tissue of the individual from deviation of mean of expression of from the mean of expression of HMGA2 and PPAR-gamma in the test group;
wherein the adipose tissue of the individual has a high proportion of pre-adipocytes and a low proportion of mature insulin-sensitive adipocytes if deviation of mean expression of HMGA2 from the mean of expression of HMGA2 in the test group is between 0.375 and 1.344 and the deviation of mean expression of PPAR-gamma in the test group is between −0.197 and 0.049;
wherein the high proportion of pre-adipocytes and a low proportion of mature insulin-sensitive adipocytes in the adipose tissue of the individual indicates an elevated risk of developing type II diabetes mellitus;
wherein if the adipose tissue of the individual has high proportion of pre-adipocytes and low proportion of mature insulin-sensitive adipocytes, the method further comprises the step of detecting type II diabetes mellitus risk factors of hypertension and/or elevated blood glucose levels comprising measuring blood pressure and/or blood glucose levels.

### Claim 2 (depends on 1)

Method according to claim 1, wherein the individual is a human being.

### Claim 3 (depends on 1)

Method according to claim 1, wherein the sample mass is ≤5 mg.

### Claim 4 (depends on 1)

Method according to claim 1, wherein the gene expression level is measured on the mRNA level relative to the gene expression level of a housekeeping gene.

### Claim 5 (depends on 1)

Method according to claim 1, wherein the RNA has a concentration≤25 ng/μl.

### Claim 6 (depends on 1)

Method according to claim 1, wherein the individual has a BMI between 23.4 kg/m2 and 36 kg/m2 and the individual is normal-weight, overweight, class I obese, or class II obese.
